Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Virus-virus Interactions Among Patients Admitted to the Hospices Civils de Lyon, During 2022 to 2025 Winters Seasons

NCT07805590 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-01-05
Last updated
2026-09-04

Condition(s) studied

Respiratory VirusesDisease Severity

Investigational drug(s) / intervention(s)

Virologic results

Virologic results: Virologic results for biological samples collected as part of the diagnosis of respiratory viral infections in patients of all ages receiving routine care, regardless of their department of origin, during the winter periods from 2022 to 2025.

Study summary

Respiratory viruses circulate throughout the year, and particularly during the winter. Consequently, co-infections involving two or more viruses can occur. The study of virus-virus interactions at the population level is necessary to understand the dynamics of co-infections. Viruses such as IAV (influenza A virus) and rhinoviruses (common cold viruses) are known to have a negative interaction, mutually excluding one another, which results in a reduced likelihood of co-infection. The study of virus-virus interactions at the population level constitutes an essential first step towards understanding and characterising these phenomena at the individual level, and subsequently at the cellular level. Using integrative approaches combining epidemiological data, clinical observations and in vitro models, it has been shown that IAV and SARS-CoV-2 have a negative interaction, whilst potentially contributing to the severity of respiratory infections. This research also suggests that prior vaccination against IAV reduces the risk of severe forms of the disease.

Furthermore, viral co-infections appear to influence the severity of respiratory infections, particularly in children. Children appear to be more susceptible to these co-infections, with around 35% of cases reported, compared with 6% in adults. In this context, the study and characterisation of virus-virus interactions appear essential to better understand the pathophysiology of respiratory infections and improve the management of co-infected patients.

Every week, Dr Jean-Sébastien Casalegno publishes the Hospices Civils' epidemiological bulletin, which considers the prevalence of respiratory viruses detected at the Centre de Biologie et Pathologie Nord. This local dataset reports on the co-circulation of respiratory viruses and is of interest for the study of virus-virus interactions at a population level.

The impact of viral co-infections on the severity of respiratory infections remains a subject of debate in the literature. Understanding the dynamics of interaction between respiratory viruses at a population level, in order to identify preferential associations or exclusions, is essential for assessing the clinical impact of co-infections.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \- Any virological result (positive or negative) following a biological sample taken as part of routine care within the HCLs for the purpose of diagnosing a respiratory infection in a hospitalised patient. * Patients of any age * Samples taken during the winter periods between 2022 and 2025. Exclusion Criteria: * na

Primary outcome measure(s)

  • Virus-virus interactions over three consecutive winters — Baseline
    To characterize virus-virus interactions from 2022 to 2025 by assessing a co-infection exclusion score in order to identify, based on PCR results from respiratory samples collected over specific time periods (months/years), the preferred (positive) associations and exclusion (negative) relationships between respiratory viruses.

Trial sites (1)

FacilityCityRegionStatus
Infective Agents Institute, Croix rousse Hospital Lyon Rhone Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07805590 on ClinicalTrials.gov ↗ ← All trials in France